Company intelligence / Profile preview

Arseus

Waregem, Belgium

Ownership: Private
Development stage: Other

Overview

Arseus was a Belgian-Dutch healthcare group listed on Euronext, primarily known for its Fagron division as a global leader in pharmaceutical compounding. It underwent major restructuring in 2014, divesting non-core units and focusing on R&D innovations like dermatology and pain management concepts. It was later acquired by Henry Schein.

Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Arseus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arseus.

Explore the full profile